Emerging role of Alemtuzumab in renal and renal–pancreas transplantation

Bibliography

• Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605-12
   PubMed Web of Science ®Google Scholar
• Meier Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289-95
   PubMed Web of Science ®Google Scholar
• Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with antibody. Am J Transplant 2007;7:2124-32
   PubMed Web of Science ®Google Scholar
• Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33
   PubMedGoogle Scholar
• Hale G, Bartholomew M, Taylor V, et al. Recognition of CD-52 allelic gene products by CAMPATH1-H antibodies. Immunology 1996;88:183-90
   PubMed Web of Science ®Google Scholar
• Yeung CH, Schroter S, Wagenfeld A, et al. Interaction of the human epididymal protein CD-52 (HE5) with epididymal spermatozoa from men and cynomolgus monkeys. Mol Reprod Dev 1997;48:267-75
   PubMed Web of Science ®Google Scholar
• Hale G, Rye PD, Warford A, et al. The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J Reprod Immunol 1993;23:189-205
   PubMed Web of Science ®Google Scholar
• Waldmann H, Hale G. CAMPATH: from concept to clinic. Philos Trans R Soc Lond B Biol Sci 2005;360:1707-11
   PubMed Web of Science ®Google Scholar
• Waldmann H, Hale G, Weiss, et al. Elimination of graft versus host disease by in vitro depletion of alloreactive lymphocytes using a monoclonal rat anti-human lymphocyte antibody (Campath-1). Lancet 1984;ii:483-6
   Google Scholar
• Dyer M, Hale G, Hayhoe F, et al. Effects of Campath-1 antibodies in vitro in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73:1431-9
   PubMed Web of Science ®Google Scholar
• Hale G, Dyer MJ, Clark MR, et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH 1-H. Lancet 1988;ii:1394-9
   Google Scholar
• Xia MQ, Tone M, Packman L, et al. Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone. Eur J Immunol 1991;21:1677-84
   PubMed Web of Science ®Google Scholar
• Xia MQ, Hale G, Lifely MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993;293:633-40
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Reis S, Hallek M. Rituximab and alemtuzumab induce a nonclassic, capsase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells. Ann Hematol 2004;83:634-45
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey UH, Roth A, et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody dependent cellular cytotoxicity. Eur J Pharmacol 2005;514:217-24
   PubMed Web of Science ®Google Scholar
• Hale G. The CD52 antigen and development of the CAMPATH antibodies. Cryotherapy 2001;3:137-43
   PubMed Web of Science ®Google Scholar
• Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003;76:120-9
   PubMed Web of Science ®Google Scholar
• Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory like phenotype are the dominant cell type following antibody mediated T-cell depletion. Am J Transplant 2005;5:465-74
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Brettman LR. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104:948-55
   PubMed Web of Science ®Google Scholar
• CAMPATH PACKAGE INSERT, Berlex Laboratories; 2001
   Google Scholar
• Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278-91
   PubMed Web of Science ®Google Scholar
• Kirk AD. Transplant tolerance: a look at a non-human primate literature in the view of modern tolerance theories. Crit Rev Immunol 1999;19:349-88
   PubMed Web of Science ®Google Scholar
• Thomas JM, Eckhoff DE, Contreras JL, et al. Durable donor-specific T and B cell tolerance in rhesus macaques induced with peritransplantation anti-CD3 immunotoxin and Deoxyspergualin: absence of chronic allograft nephropathy. Transplantation 2000;69:2497-503
   PubMed Web of Science ®Google Scholar
• Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with Deoxyspergualin. Transplantation 2005;80:1051-9
   PubMed Web of Science ®Google Scholar
• Calne R, Moffatt SD, Friend PJ, et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613-6
   PubMed Web of Science ®Google Scholar
• Watson JEC, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation – efficacy and safety at five years. Am J Transpl 2005;5:1347-53
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath 1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004;78:426-33
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. Campath-1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up. Transplantation 2008;85:507-16
   PubMed Web of Science ®Google Scholar
• Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005;80:765-74
   PubMed Web of Science ®Google Scholar
• Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant 2008;8:1480-5
   PubMed Web of Science ®Google Scholar
• Tan HP, Kaczorowski A, Basu A, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006;6:2409-17
   PubMed Web of Science ®Google Scholar
• Tan HP, Donaldson J, Basu A, et al. Living donor kidney transplants using alemtuzumab preconditioning and tacrolimus monotherapy [abstract 137]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Tan HP, Kaczorowski A, Basu A, et al. Living-related donor kidney transplantation in HIV + recipients using alemtuzumab preconditioning and steroid free tacrolimus monotherapy: a single center preliminary experience. Transplantation 2004;78:1683-8
   PubMed Web of Science ®Google Scholar
• Ortiz J, Palma Vargas J, Wright F, et al. Campath induction for kidney transplantation: report of 297 cases. Transplantation 2008;85:1550-6
   PubMed Web of Science ®Google Scholar
• Baez Y, Giron F, Nino Murcia A, et al. Experience with alemtuzumab 9Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. Transplant Proc 2008;40:697-9
   PubMed Web of Science ®Google Scholar
• Ravindra K, Ouseph R, Eng M, et al. Alemtuzumab induction with steroid sparing immunosuppression in high risk kidney transplantation [abstract 1548]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Charif R, Chan K, Canelo R, et al. Campath induction and tacrolimus monotherapy in simultaneous kidney and pancreas transplantation [abstract 1411]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Mota A, Arias M, Taskinen E, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004;4:953-9
   PubMed Web of Science ®Google Scholar
• Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004;4:1776-85
   PubMed Web of Science ®Google Scholar
• knechtle SJ, Pirsch JD, Fechner JH, et al. Campath-1H induction plus Rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003;3:722-30
   PubMed Web of Science ®Google Scholar
• Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006;19:885-92
   PubMed Web of Science ®Google Scholar
• Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005;5:3009-14
   PubMed Web of Science ®Google Scholar
• Gruessner RWG, Kandaswamy R, Humar A, et al. Calcineurin inhibitor and steroid-free immunosuppression in pancreas-kidney and solitary pancreas transplantation. Transplantation 2005;79:1184-9
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing and newer immune monitoring. Transplantation 2005;80:457-65
   PubMed Web of Science ®Google Scholar
• Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008;22:200-10
   PubMed Web of Science ®Google Scholar
• Chan K, Taube D, Galliford J, et al. Randomized controlled trial of Campath and tacrolimus-monotherapy with daclizumab, tacrolimus and mycophenolate mofetil in renal transplantation; interim results [abstract 139]. Am Transplant Congress; 2008; Toronto
   PubMedGoogle Scholar
• Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction – long-term results. Am J Transplant 2005;5:2539-48
   PubMed Web of Science ®Google Scholar
• Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: the University of Wisconsin experience. Surgery 2004;136:754-60
   PubMed Web of Science ®Google Scholar
• Mohanka R, Basu A, Shapiro R, Kayler L. Campath induction associated with reduced delayed graft function (DGF) in kidney transplantation [abstract 971]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007;83:1509-12
   PubMed Web of Science ®Google Scholar
• Hanaway M, Woodle SE, Mulgaonkar S, et al. 12 month results of a multicenter, randomized trial comparing three induction agents (alemtuzumab, thymoglobulin and basiliximab) with tacrolimus, mycophenolate mofetil and a rapid steroid withdrawal in renal transplantation [abstract 135]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after Pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005;20:505-15
   Google Scholar
• Shapiro R, Zeevi A, Basu A, et al. Alemtuzumab preconditioning with tacrolimus monotherapy-The impact of serial monitoring of donor-specific antibody. Transplantation 2008;85:1125-32
   PubMed Web of Science ®Google Scholar
• Schadde E, Dalessandro AM, Knechtle SJ, et al. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transpl Int 2008;21:625-36
   PubMed Web of Science ®Google Scholar
• Kaufman DB, Levinthal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction – Long-term results. Am J Transplant 2006;6:331-9
   PubMed Web of Science ®Google Scholar
• Farney A, Sundberg A, Moore P, et al. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008;22:41-9
   PubMed Web of Science ®Google Scholar
• Farney AC, Singh R, Rogers J, et al. A prospective randomized study of alemtuzumab vs rabbit antithymocyte globulin induction in kidney and pancreas transplantation [abstract 532]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Huang E, Cho YW, Hayashi R, Bunnapradist S. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007;84:821-8
   PubMed Web of Science ®Google Scholar
• Bunnapradist S, Gill J, Takemoto S, Shah T. Kidney transplant outcomes with alemtuzumab and Thymoglobulin induction [abstract 136]. Am Transplant Congress; 2008; Toronto
   PubMedGoogle Scholar
• Friend PJ, Rebello P, Oliveria D, et al. Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody. Transplant Proc 1995;27:869-70
   PubMed Web of Science ®Google Scholar
• Csapo Z, Benavides VC, Podder H, et al. Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc 2005;37:2032-6
   PubMed Web of Science ®Google Scholar
• Basu A, Ramkumar M, Tan HP, et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. Transplant Proc 2005;37:923-6
   PubMed Web of Science ®Google Scholar
• Peleg AY, Hussain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007;44:204-12
   PubMed Web of Science ®Google Scholar
• Pascual J, Pirsch J, Torrealba J, et al. Antibody mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction [abstract 222]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Zang PL, Malek SK, Prichard JW, et al. Acute cellular rejection predominated by monocytes in a severe form of rejection in human renal recipients with or without Campath-1H (alemtuzumab) induction therapy. Am J Transpl 2005;5:604-7
   PubMed Web of Science ®Google Scholar
• Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immulogic self-tolerance. J Immunol 1999;162:5317-26
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Regulatory T-cell: key controllers of immunologic self-tolerance. Cell 2000;101:455-8
   PubMed Web of Science ®Google Scholar
• Bloom DD, Chang C, Fechner JH, et al. CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8:793-802
   PubMed Web of Science ®Google Scholar
• Segundo DS, Ruiz JC, Izquierdo M, et al. Calcineurin inhibitors, but not Rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006;82:550-7
   PubMed Web of Science ®Google Scholar
• Norris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 2007;18:1007-18
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin M, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6:1142-51
   PubMed Web of Science ®Google Scholar
• Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: progress, challenges and prospects. Am J Transplant 2007;7:1457-63
   PubMed Web of Science ®Google Scholar
• Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008;8:1529-36
   PubMed Web of Science ®Google Scholar
• Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-37
   PubMed Web of Science ®Google Scholar
• Malek SK, Obmann MA, Gotoff RA, et al. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006;81:17-20
   PubMed Web of Science ®Google Scholar
• Ashcraft E, Farney A, Hartmann E, et al. A prospective randomized single center trial of alemtuzumab versus rabbit anti-thymocyte globulin induction in renal and pancreas transplantation: infectious complications [abstract 983]. Am Transplant Congress; 2008; Toronto
   Google Scholar
• Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and post transplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7:2619-25
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691-5
   PubMed Web of Science ®Google Scholar
• Kirk AD, Hale DA, Swanson SJ, Mannon RB. Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab. Am J Transplant 2006;6:1084-5
   PubMed Web of Science ®Google Scholar
• Taylor VC, Sims M, Brett S, Field MC. Antibody selection against CD52 produces a paroxysmal nocturnal hemoglobinuria phenotype in human lymphocytes by a novel mechanism. Biochem J 1997;322:919-25
   PubMed Web of Science ®Google Scholar
• Focarelli R, Francavilla S, Francavilla F, et al. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologous of the leukocyte CD52 antigen: Analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1H) on capacitated spermatozoa. Mol Hum Reprod 1999;5:46-51
   PubMed Web of Science ®Google Scholar
• Sachdeva A, Matuschak GM. Diffuse alveolar hemorrhage following alemtuzumab. Chest 2008;133:1476-8
   PubMed Web of Science ®Google Scholar
• Ku G, Ting WC, Lim ST, Lee BT, Calne RY. Life-threatening coagulopathy associated with use of Campath (alemtuzumab) in maintenance steroid-free renal transplant given before surgery. Am J Transplant 2008;8:84-886
   Web of Science ®Google Scholar
• Pascual J, Mezrich JD, Djamali A, et al. Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. Transplantation 2007;83:1429-34
   PubMed Web of Science ®Google Scholar